<div id="readability-page-1"><p><span>Cullinan Therapeutics (NASDAQ:CGEM - Get Free Report)</span>'s stock had its &#34;outperform&#34; rating restated by equities researchers at Wedbush in a note issued to investors on Thursday,RTT News reports. They currently have a $25.00 price objective on the stock. Wedbush's price target points to a potential upside of 186.70% from the company's current price.</p><p>Other research analysts have also recently issued research reports about the company. New Street Research  set a $26.00 price target on Cullinan Therapeutics in a research note on Thursday. HC Wainwright lifted their target price on Cullinan Therapeutics from $24.00 to $26.00 and gave the company a &#34;buy&#34; rating in a research note on Thursday. Weiss Ratings  reiterated a &#34;sell (e+)&#34; rating on shares of Cullinan Therapeutics in a research report on Wednesday, October 8th. BTIG Research  reiterated a &#34;buy&#34; rating and set a $32.00 price target on shares of Cullinan Therapeutics in a research report on Wednesday, September 10th. Finally, Zacks Research upgraded shares of Cullinan Therapeutics from a &#34;strong sell&#34; rating to a &#34;hold&#34; rating in a research note on Tuesday, September 16th. Six investment analysts have rated the stock with a Buy rating, one  has assigned  a Hold rating and one  has issued  a Sell rating to the company. Based on data from MarketBeat.com, Cullinan Therapeutics presently has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $26.14.</p><div><p><span></span><span>Get <strong>Cullinan Therapeutics</strong> alerts:</span></p></div><p><b>View Our Latest Report on Cullinan Therapeutics</b></p><h2>Cullinan Therapeutics Stock Performance</h2><p>NASDAQ CGEM traded up $0.27 during mid-day trading on Thursday, reaching $8.72. 1,080,404 shares of the stock were exchanged, compared to its average volume of 810,446. Cullinan Therapeutics has a 1-year low of $5.68 and a 1-year high of $13.78. The business's fifty day simple moving average is $7.28 and its 200 day simple moving average is $7.65. The stock has a market capitalization of $515.18 million, a PE ratio of -2.63 and a beta of -0.07. </p><p>Cullinan Therapeutics (NASDAQ:CGEM - Get Free Report) last released its earnings results on Thursday, November 6th. The company reported ($0.77) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.95) by $0.18.  On average, analysts anticipate that  Cullinan Therapeutics will post -3.04 EPS for the current year. </p><h2>Insider Activity at Cullinan Therapeutics</h2><p>In other Cullinan Therapeutics news, major shareholder Lynx1 Capital Management Lp acquired 626,043 shares of Cullinan Therapeutics stock in a transaction dated Thursday, October 9th. The stock was bought at an average cost of $6.70 per share, with a total value of $4,194,488.10. Following the completion of the transaction, the insider owned 8,271,786 shares of the company's stock, valued at $55,420,966.20. The trade was a 8.19% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities &amp; Exchange Commission, which is accessible through this hyperlink. Insiders bought 1,874,057 shares of company stock valued at $13,325,286 in the last 90 days. Insiders own  7.16% of the company's stock. </p><h2>Institutional Trading of Cullinan Therapeutics</h2><p>A number of institutional investors and hedge funds have recently added to or reduced their stakes in CGEM. Trexquant Investment LP acquired a new position in shares of  Cullinan Therapeutics during the first quarter worth approximately $518,000.  Wellington Management Group LLP raised its stake in shares of  Cullinan Therapeutics by 21.1% in the first quarter. Wellington Management Group LLP now owns 161,057 shares of the company's stock valued at $1,219,000 after buying an additional 28,081 shares during the period.  Russell Investments Group Ltd. purchased a new stake in shares of  Cullinan Therapeutics during the 1st quarter valued at approximately $222,000.  Voss Capital LP lifted its holdings in  Cullinan Therapeutics by 43.0% during the 1st quarter. Voss Capital LP now owns 175,000 shares of the company's stock worth $1,325,000 after purchasing an additional 52,639 shares in the last quarter.  Finally, Rhumbline Advisers grew its position in shares of  Cullinan Therapeutics by 4.6% during the 1st quarter. Rhumbline Advisers now owns 71,338 shares of the company's stock valued at $540,000 after purchasing an additional 3,130 shares in the last quarter. Institutional investors own  86.31% of the company's stock. </p><h2>Cullinan Therapeutics Company Profile</h2> (Get Free Report)<p>Cullinan Therapeutics, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.</p><h2>Read More</h2><ul><li>Five stocks we like better than Cullinan Therapeutics</li><li>Most active stocks: Dollar volume vs share volume</li><li>Datavault AI Just Raised Guidance by 400%—Are You Paying Attention?</li><li>Best ESG Stocks: 11 Best Stocks for ESG Investing</li><li>Peter Thiel Dumps NVIDIA and Slashes Tesla Stake—Is the AI Bubble About to Pop?</li><li>What Do S&amp;P 500 Stocks Tell Investors About the Market? </li><li>Why Lithium Americas Could Be a 2030 Power Play—Not a 2025 One</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0dFTQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="600" height="385" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0dFTQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Cullinan Therapeutics Right Now?</h2><p>Before you consider Cullinan Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cullinan Therapeutics wasn't on the list.</p><p>While Cullinan Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

CGEM

<p>Wedbush reaffirmed an "outperform" rating for Cullinan Therapeutics, setting a $25 price target, indicating a potential upside of 186.70%. Other analysts have issued ratings ranging from "buy" to "sell" with price targets between $24 and $32. The stock traded at $8.72, with a market cap of $515.18 million. Insider and institutional activities show significant stock acquisitions and holdings. Cullinan focuses on developing oncology therapies, with several programs in Phase I clinical trials.</p>

Cullinan Therapeutics' (CGEM) "Outperform" Rating Reaffirmed at Wedbush